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are extensively used for predicting biological activity as 
well as toxicity during small molecule drug development; 
however, their full potential has not been utilized for bio-
logical drug development. The scope of in vitro and in 
silico tools in early developmental stages of monoclonal 
antibody-based therapeutics production and how it contrib-
utes to lower attrition rates leading to faster development of 
potential drug candidates has been evaluated. The applica-
bility of computational toxicology approaches in this con-
text as well as the pitfalls and promises of extending such 
techniques to biopharmaceutical development has been 
highlighted.
Keywords Predictive toxicology · Monoclonal antibody-
based therapeutics · Safety pharmacology · In vitro and in 
silico tools · QSAR
Introduction
The pharmaceutical industry is currently valued at $786 bil-
lion from the total worldwide sales of prescription as well 
as over the counter drugs in 2015 wherein 25 % of this rev-
enue was generated by biological/biotechnological prod-
ucts (Pharma 2014). Biological drugs are associated with 
living entities (cells and tissues) and/or their product such 
as recombinant therapeutic proteins and vaccines to name 
a few. Based on historical data, a shift towards biologics 
seems imminent owing to increasing profits and lower attri-
tion rates when compared to small molecule drugs. Biolog-
ical drugs comprised 70 % of the top ten selling products 
of the world in 2014, and the percentage sales of biotech-
nology products within the top 100 was 44 %. Twenty new 
biologicals were approved by FDA in 2014 compared to 
the 11 that were approved in 2009. Monoclonal antibodies 
Abstract Biopharmaceuticals, monoclonal antibody 
(mAb)-based therapeutics in particular, have positively 
impacted millions of lives. MAbs and related therapeutics 
are highly desirable from a biopharmaceutical perspective 
as they are highly target specific and well tolerated within 
the human system. Nevertheless, several mAbs have been 
discontinued or withdrawn based either on their inabil-
ity to demonstrate efficacy and/or due to adverse effects. 
Approved monoclonal antibodies and derived therapeutics 
have been associated with adverse effects such as immu-
nogenicity, cytokine release syndrome, progressive mul-
tifocal leukoencephalopathy, intravascular haemolysis, 
cardiac arrhythmias, abnormal liver function, gastrointes-
tinal perforation, bronchospasm, intraocular inflammation, 
urticaria, nephritis, neuropathy, birth defects, fever and 
cough to name a few. The advances made in this field are 
also impeded by a lack of progress in bioprocess develop-
ment strategies as well as increasing costs owing to attri-
tion, wherein the lack of efficacy and safety accounts for 
nearly 60 % of all factors contributing to attrition. This reit-
erates the need for smarter preclinical development using 
quality by design-based approaches encompassing care-
fully designed predictive models during early stages of 
drug development. Different in vitro and in silico methods 
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have higher approval rates of 26 % in the biopharmaceuti-
cal sector than that of conventional small molecule drugs 
(10 %) (Hay et al. 2014). Based on the area of therapy, the 
largest segments of oncology and anti-rheumatoid drugs, 
which contribute to a combined compound annual growth 
rate of 13 %, continue to be dominated by biological drugs.
Even though the therapeutic efficiency of immuno-
globulin molecules was demonstrated in 1890, it was only 
after Kohler and Milstein elucidated the murine hybridoma 
technology for in vitro production of mAbs (see Fig. 1 for 
generic mAb structures) that the market for mAbs grew and 
expanded to different therapy areas, such as haematology, 
oncology, immunology, cardiology, infectiology and oph-
thalmology as well as diagnostics and imaging(Köhler and 
Milstein 1975). The shift from murine mAbs to chimeric 
(human Fc region with murine Fv region) was mainly to 
increase titres as well as decrease immunogenic effects 
(Zhu 2012). To further decrease the murine composition 
and enhance Fc functionality, humanized mAbs were first 
developed in 1986 (Jones et al. 1985). The production sys-
tems routinely used for chimeric and humanized mAbs are 
Chinese hamster ovary (CHO) cells, NS0 and Sp2/0 mye-
loma cell line. To fully eliminate the immunogenic poten-
tial of murine epitopes while maintaining optimal Fc region 
functionality, fully human mAbs were developed by phage 
display technology and commercially produced by CHO 
system (Lai et al. 2013). Human embryonic kidney (HEK) 
and human retinal cell-derived (Per.C6) cell lines are the 
new potential candidates for biopharmaceutical produc-
tion (Zhu 2012). In addition to being stable and producing 
high titres, the fully human cell lines offer the advantage 
of proper post-translation modification and glycosylation 
as they incorporate human biosynthetic pathways. Plant 
expression systems, such as recombinant Agrobacterium 
tumefaciens, and microbial systems, such as Escherichia 
coli, are gaining popularity for production of monoclo-
nal antibodies against viruses (Berlec and Štrukelj 2013; 
Rosenberg et al. 2013; Ma et al. 2003). Transfected HEK 
cells have already been used to produce recombinant coag-
ulation factors which have been approved by FDA (Food 
and Drug Administration); however, full length mAbs 
produced by them are still awaiting approval (Lai et al. 
2013; Berlec and Štrukelj 2013). Furthermore proprietary 
technologies, such as VelocImmune®, BiTE®, POTELLI-
GENT™, UltiMAb® and XenoMouse®, are used for pro-
duction of monoclonal antibodies (Jakobovits et al. 2007; 
Murphy 2009; Nelson and Paulos 2015; Sheridan 2010; 
Shitara 2009). The mAb-derived products include fusion 
proteins, antigen binding fragments as well as composite 
proteins (Lefranc et al. 2009; Povey et al. 2001; Ecker et al. 
2015; Li and Zhu 2010).
MAbs: safety pharmacology and side effects
MAbs and related therapeutics are highly desirable from a 
biopharmaceutical perspective as they are highly target spe-
cific and well tolerated within the human system. Never-
theless, several mAbs have been discontinued or withdrawn 
based either on their inability to demonstrate efficacy and/
or due to adverse effect, for example, Efalizumab, Biciro-
mab and Fanolesomab, while others were discontinued due 
to high manufacturing costs, for example, Imciromab and 
Fig. 1  Generic monoclonal 
antibody-derived therapeutic 
structures as adapted from 
IMGT (Lefranc et al. 2009; 
World Health O 2006). Fc con-
stant region which contributes 
to effector function, immune 
response and increased half-life, 
Fv variable region that contains 
complementarity determining 
regions (CDRs) facilitating 
antigen binding, Fab antigen 
binding fragment which lacks 
Fc region, scFv single chain 
fragment variable, FP Fc fusion 
proteins that contain Fc region 
for effector functionality (e.g. 
Abatacept), CP composite 
protein that contains Fc region 
for increasing half-life and not 
for effector functionality (e.g. 
Strensiq™) (World Health 
2006)
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Arcitumomab (Lefranc et al. 2009). Approved monoclonal 
antibodies as well as derived products have been associ-
ated with adverse effect, and these effects have been clas-
sified into categories of specialized toxicity as indicated in 
Table 1 (Peluso et al. 2013; Hansel et al. 2010). The report-
ing of these adverse effects is to be treated with caution as 
there are several factors that influence them, such as under-
lying conditions, drug combinations, reporting practices 
and clinical practice involved in the clinical trials.
The catastrophic TGN1412 clinical trial that resulted in 
multiple organ failure of six healthy volunteers reiterated 
the need for better preclinical safety testing. The underly-
ing problems that were subsequently identified in this trial 
were mainly the lack of appropriate preclinical testing and 
model organisms chosen for study of adverse effects. The 
standard in vitro assays failed to capture the in vivo adverse 
effects in humans (Stebbings et al. 2013). In vivo toxicity 
studies using rodent or primate models are not always rep-
resentative of the human system. Human therapeutics such 
as monoclonal antibodies are highly specific and targeted, 
and there is, therefore, a higher likelihood of false posi-
tive efficacy or false negative toxicity if such entities are 
tested in non-human models, both outcomes being highly 
undesirable.
Eloctate showed haemotoxicity and hepatotoxicity in 
animal studies (mice and monkeys), but none have been 
reported in human clinical trials (Lower 2015). TGN1412 
did not show the pro-inflammatory cytokine storm in 
in vivo tests (cynomolgus macaques) due to the absence of 
CD28 on its CD4+ effector memory T cells as well as in 
in vitro tests (human lymphocytes) due to the lack of local-
ization of cell receptor (Stebbings et al. 2013). There are 
different factors which can influence the safety and efficacy 
of mAbs. Binding affinity, glycoforms, valency and den-
sity of antigens as well as antibodies, cell surface receptor 
and binding interface are some of the factors that contrib-
ute to the biological activity of mAbs and, if suboptimal, 
could lead to reduction of efficacy or an increase in toxicity 
(Stebbings et al. 2013; Jefferis 2014). Nimotuzumab exhib-
its lower dermal toxicity due to optimal binding affinity to 
EFGR that ensures its binding below toxic levels (Boland 
and Bebb 2009).
Effector functions of mAbs and related products, such as 
antibody-dependent cell phagocytosis (ADCP), antibody-
dependent cytotoxicity (ADCC), complement-dependent 
cytotoxicity (CDC) as well as evoking other cell-medi-
ated immune responses, are modulated via the Fc region 
by interaction with FcγR receptors on different immune 
responsive cells (Fig. 2a) (Carter 2006). This also regulates 
the pharmacokinetics, transcytosis, catabolism and placen-
tal transfer of antibodies via the FcRn (neonatal Fc Recep-
tor) as summarized in Table 2 (Roopenian and Akilesh 
2007). Glycosylation at the Fc region occurs at N297 
and consists of a core heptasaccharide region compris-
ing mostly N-acetylglucosamine and mannose residues as 
well as the variable region as seen in Fig. 2b (Carter 2006). 
Modifying the Fc region either via amino acid substitution 
or by a change in glycosylation pattern has shown to change 
effector functionality. IgG1-based therapeutic antibodies 
have shown increased ADCC and ADCP activity with sub-
stitution at amino acid positions 298,333 and 334, whereas 
Otelixizumab has shown reduced ADCP and ADCC activ-
ity with an N297A substitutions(Shields et al. 2001; Bolt 
et al. 1993).The mammalian cell production systems could 
alter the glycoform, and this could either change the effec-
tor function-mediated therapeutic activity or induce immu-
nogenic effects of mAbs (Jefferis 2009). Afucosylation and 
bisecting N-acetylglucosamine were reported for antibod-
ies produced in CHO cells, and they were associated with 
reduced ADCC activity (Shields et al. 2002; Umaña et al. 
1999). Galactosylation levels are important for different 
functions, such as transport of IgG molecules across pla-
centa and complement activation. Mammalian cell lines 
generally produce hypogalactosylated products; however, 
if this hypogalactosylation is unintended, it could impact 
effector function. This has been demonstrated with Alem-
tuzumab and rituximab where the removal of galactose 
residues reduced complement activation (Raju and Jordan 
2012; Boyd et al. 1995). Mammalian production systems 
can also add oligosaccharides not present in human system, 
such as addition of N-glycolylneuraminic acid by CHO, 
NS0 and Sp2/0 systems, which can be immunogenic (Jef-
feris 2014). 
Although the trends seem to be in favour of biopharma-
ceutical development, the growth rates have not yet reached 
their full potential due to financial and technical complexi-
ties involved in early stages of research and development 
and preclinical testing as described in the following sec-
tions. The comprehensive costs of developing a new drug 
amount to $2.8 billion (Pharma 2014). Studies done over 
the past decade show that nearly 90 % of drugs failed in 
clinical development (66 % in Phase I and 30 % in Phase II) 
and this high attrition rate is the major contributing factor 
to the exorbitant cost of new drug development (Hay et al. 
2014; Kola and Landis 2004; Paul et al. 2010). Thus, it is 
more beneficial to address attrition, as a 10–15 % decrease 
in attrition rate could reduce the cost of drug development 
by nearly 35 % (Paul et al. 2010). Recent studies reported 
that toxicity and lack of efficacy were the most important 
factors for high attrition rates in small molecule drug devel-
opment (Waring et al. 2015). Unlike conventional drugs 
which mainly revolve around small molecule chemistry, 
biological drugs are far more complex to produce and char-
acterize as they are 200–1000× larger, structurally more 
complex and highly sensitive to their manufacturing con-
ditions. The costs involved in development and production 
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of biopharmaceutical entities are 1.5–2.5× higher than that 
of small molecule drugs (Blackstone and Fuhr 2007). With 
nearly 80 % of biological drugs failing in clinical develop-
ment mainly due to lack of efficacy and safety, there arises 
an urgent need for smarter preclinical development. This 
requires better product understanding, i.e. examining char-
acteristics which contribute to product quality such as bio-
logical activity, affinity, pharmacology, toxicity, immuno-
genicity, thus leading to early prediction of success/failure. 
Improved product understanding and rapid screening of 
potential drug candidates by utilizing different in vitro and 
in silico methods to predict efficacy and safety techniques 
would lead to better preclinical design.
In vitro systems for toxicity testing
The general in vitro toxicity testing panel includes cel-
lular, biochemical and molecular assays to study cyto-
toxicity, reactive oxygen species production as well as 
specialized toxicity effects including genotoxicity, hepato-
toxicity, immunotoxicity to name a few. They are assessed 
via standard, specialized or target organ cell-based assays. 
Techniques such as WST, MTT, MTS, BrDu and Alamar 
blue are commonly used to asses basal cytotoxic or direct 
effect on cell proliferation, whereas Annexin V/Propidium 
iodide staining can help distinguish between necrotic and 
apoptotic events. Mitochondrial damage can be assessed 
by mitochondrial membrane potential assays and lumi-
nescent cell viability assays that quantify ATP. Protein 
marker-based techniques, such as assessing caspase cleav-
age via flow cytometry or western blotting techniques, 
can also be used to understand the mode of action of par-
ticular compounds. Reactive oxygen species production 
leads to oxidative stress, and this can also lead to cellu-
lar damage. There are different dyes, such as fluorescent 
and bioluminescent dyes, that can be utilized to study this 
effect. For gauging specialized toxicity effects, differ-
ent types of biochemical, molecular and mode of action-
based endpoints can be utilized. In vitro experimental 
data when combined with physicochemical properties 
and absorption, distribution, metabolism and elimination 
(ADME) characteristics help establish physiologically 
Fig. 2  a Monoclonal antibody structure with binding site for antigen, 
FcγR and FcRn receptor as well as glycosylation sites (Glycan); Ag 
antigen, CDC complement-dependent cytotoxicity, ADCC antibody-
dependent cell cytotoxicity, ADCP antibody-dependent cell phago-
cytosis, b glycosylation profile at N297 residue of the Fc region of 
antibodies. The bold line indicates core structures, and dotted line 
indicates variable structures. Gal galactose, SA sialic acid, man man-
nose, GlcNAc N-acetylglucosamine, Fuc fucose, Asn asparagine 
(N297)
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Table 2  IgG receptors and effector functions
Bold: IgG1, italic IgG2
Bolditalic: IgG3
Underline: IgG4
NA not applicable, AA amino acid
**** Very high affinity
*** High affinity
** Moderate affinity
* Low affinity;—no binding
I Inducible expression
a Low percentages
b Liu (2015)
Function Binding affinity Expression Important AA residues Impact of glycosyla-
tionb
IgG subclass Ka (106 M−1)
C1q CDC **
*
***
–
NA
NA
NA
NA
Present in serum L235, D265, D270, 
K322, P329, P331, 
H433
Galactose: ↑ CDC;
Mannose: ↓ CDC
FcγRI Activation ***
–
****
**
65
–
61
34
Monocytes,  
macrophages
Dendritic Cells
NeutrophilsI
Mast CellsI
E233, L235, G236 Unclear
FcγRIIA (H131) Activation ***
**
****
**
5.2
0.45
0.89
0.17
Monocytes,  
macrophages
Dendritic Cells
Neutrophils
Mast Cells
Basophils
Eosinophils
L234, L235, G236, 
A327
Unclear
FcγRIIA (R131) ***
*
****
**
3.5
0.10
0.91
0.21
FcγRIIB/C Inhibition *
–
**
*
0.12
0.02
0.17
0.20
B cells
Dendritic cells
Basophils
Monocytesa
Macrophagesa
Neutrophilsa
Unclear Unclear
FcγRIIIA (F158) Activation **
–
****
–
1.2
0.03
7.7
0.20
Natural killer cells
Monocytes
Macrophages
E233, L234, 
L235G236
Mannose, Bisecting 
GlcNac:↑ ADCC;
Sialic acid, fucose:  
↓ ADCC
FcγRIIIA (V158) ***
*
****
**
2.0
0.07
9.8
0.25
FcγRIIIB Unclear ***
–
****
–
0.2
–
1.1
–
Neutrophils
Basophils
L234, L235G236, 
G237, P238
Unclear
FcRn Transcytosis
Catabolism
Antigen uptake
***
***
**/****
***
80
NA
NA
NA
Monocytes,  
macrophages,  
Dendritic Cells
Neutrophils
Endothelium
Syncytiotrophoblast
H433, N434, H435, 
Y436
Galactose, Mannose, 
GlcNAc:  
↑ Clearance
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based pharmacokinetic (PBPK) and partitioning mod-
els (based on fundamental thermodynamic principles). 
Metabolism of parent compound, toxicity and likelihood 
of metabolites also allow for a more robust model to be 
developed as they help to take into account biotransfor-
mation and bioavailability. The above information helps 
to identify the doses and the class of compounds that have 
to be further tested in in vivo tests as specified by OECD 
guidelines for toxicity testing.
Monoclonal antibodies evoke an effector response 
mainly via antibody-dependent cytotoxicity, phagocyto-
sis and complement-dependent cytotoxicity for eliminat-
ing tumour target cells (Kindt et al. 2007). For testing the 
biological activity of mAb-based therapeutics in vitro, the 
target cell line is cocultured with the molecule as well as 
effector cells derived either from PBMCs in human blood 
or cultured effector cells in a defined target to effector ratio 
(Golay et al. 2013). These effects can be studied by tech-
niques which involve loading target cells with fluorescent 
membrane permeable dyes that are released upon target cell 
lysis. To assess mast cell degranulation, in vitro systems are 
incubated with drug of interest, and endpoints like hista-
mine are then measured via spectroscopy or flow cytometry 
(Demo et al. 1999). Alternatively specific biomarkers like 
complement fragments can be used to detect specific events 
such as complement activation (Golay and Introna 2012). 
Cytokine release assays provide information about the 
extent and the kind of pro-inflammatory cytokine release. 
This is often assessed by introducing the monoclonal anti-
body to human lymphocytes and then assessing the super-
natant for different types of cytokines, and this assay can 
often be performed in a multiplex format with flow cytom-
eter analysis (Lash et al. 2006). A cytokine storm is a life-
threatening adverse effect induced by monoclonal antibod-
ies such as in the case of TGN1412 (Suntharalingam et al. 
2006). Animal models utilized for assessing immunotox-
icity involve lymph node proliferation assay, local lymph 
node assay and more recently the mouse drug allergy 
model though the predictive ability of these in vivo models 
have not been well characterized or validated (Whritenour 
et al. 2016). For assessing specialized toxicity assays, spe-
cific endpoints or biomarkers can be studied. Drug induced 
liver injury, liver enzyme inhibition or induction (particu-
larly cytochromes 450, flavin monooxygenases and numer-
ous others), change in human pregnane X Receptor activ-
ity as well as drug transporter activities for hepatotoxicity; 
Ames test for mutagenicity, in vitro single cell electropho-
resis (comet) assay and DNA-based dyes for genotoxicity; 
human ether-related à-gogo gene related (hERG) assays, 
prolongation of QT interval, patch clamp assay, embryonic 
stem cell differentiation assay for cardiotoxicity and so on 
are examples used in small molecule drug development 
(Ekins 2014).
These issues regarding pharmacodynamics, selection of 
model organism, route of administration, dose, metabolism, 
toxicity studies have been addressed by the ICH Safety 
Pharmacology guideline S6 (R1) Preclinical Safety Evalua-
tion of Biotechnology-Derived Pharmaceuticals. The safety 
pharmacology of mAbs, however, cannot be optimally 
assessed by standard toxicological assays alone (Cavagnaro 
2002; Guideline 1997).
In silico tools for predictive toxicology
Computational toxicology tools could substantially aid 
in safety pharmacology testing of monoclonal antibody-
derived therapeutics as they impart elements of automa-
tion, consistency and reliability to standard toxicological 
assays. There are a multitude of advantages offered by 
computational toxicology methods. They help to realize the 
3R principle, i.e. replacement, reduction and refinement, 
by reducing the number of experimental animals used in 
drug safety testing. They also address the practical and 
economical concern of industries by providing a rapid and 
cost-effective way for safety testing of novel drug mole-
cules. This in turn helps to cut down attrition rates and thus 
reduce the financial burden on the discovery and the devel-
opment of new drugs. Furthermore, computational toxicol-
ogy methods help to prioritize testing of those compounds 
which could be associated with toxic hazards by virtue of 
a problematic chemical space. This could be by means of 
structural similarity, indiscriminate interaction with closely 
related pharmacological targets and/or off target effect or 
other molecular events which are adaptable to in silico 
methods. Computational toxicology methods also prove 
useful when animal studies do not adequately represent the 
fate of drugs in humans (Ekins 2014; Cronin and Madden 
2010; Greene and Pennie 2015; Wilson 2011).
Though these in vitro and in silico methods, such as 
physiologically based pharmacokinetic (PBPK) model-
ling and qualitative/quantitative structure–activity relation-
ships (QSAR), are extensively used for predicting biologi-
cal activity as well as toxicity during small molecule drug 
development (Table 3), their full potential has not been uti-
lized for biological drug development.
Predictive model development
From the different in silico tools listed in Table 3, a sum-
marized workflow for predictive toxicology model develop-
ment is depicted in Fig. 3a. The main question to consider 
while developing a computational model is what can be 
modelled? The starting point of model development is data 
which can be of different types such as numeric, categori-
cal, discrete or continuous and can be acquired from differ-
ent sources like experiments, structures, physicochemical 
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Table 3  Comprehensive overview of in silico prediction tools for assessing toxicology
Name Particulars Accessibility Owned by
ACD ToxSuite Molecular fragment QSAR and knowledge  
expert system, (Perceptra platform) employing 
machine learninga,h,i,j,k,l,m,r,s
Commercial ACD Labs, Pharma algorithms
Admensa interactive™ QSAR-based systemh,k,l Commercial Inpharmatica Ltd.
ADMET™ predictor QSAR-based expert system and machine 
learningb,c,d,e,f,j,k
Commercial Stimulation Plus Inc.
ADMEWORKS Predictor QSAR,QSPR-based expert systema,b,l Commercial Fujitsu, Poland
AIM Category formation and read across Free US EPA
BfR decision support system SAR and physicochemical exclusion rule-based  
system. Employs concordance decision tree 
approachd,i,o
Free German Federal Institute  
for Risk Assessment
BioEpisteme Molecular descriptor QSARb,h,k,n Commercial Prous Institute for Biomedical 
Research, Spain
Bio-loom QSAR database CLOGP, CMRh,j Commercial Biobyte
CAESAR QSAR-based expert systems based on Dragon  
descriptors and Multivariate approachesa,b,d,e
Free EU
CaseUltra (MC4PC) Molecular fragment QSAR-based expert system  
using machine learninga,b,c,d,I,j,k
Commercial MultiCASE Inc.
Cerius2/Material Studio Molecular modelling softwarek,l Commercial Accelrys Inc.
COMPACT SAR and knowledge-based system employs  
molecular orbital descriptorsa,b,c,k
Free US NTP
CSgenoTOX QSAR-based system and machine  
learning(ANN)a
Commercial ChemSilico
DEREK NEXUS SAR knowledge-based expert systema,b,c,d,e Commercial Lhasa Ltd.
HazardExpert (ToxAlert) QSAR knowledge-based expert systema,b,d,e,n,o,p Commercial Compudrug Inc.
Insilicofirst Common user interface expert system Commercial Lhasa Ltd., Leadscope,  
Multicase, MN GmbH
KNIME® QSAR workflow tool Open KNIME.com
LAZAR KNN approach (machine learning)a,b,k Open source In silico toxicology GmbH
Leadscope model applier QSAR and expert rule-based knowledge 
systemb,c,e,g,h,k,n
Commercial Leadscope Inc.
MDL QSAR Molecular descriptor QSAR, QSPR, multivariate 
approachesa,b,h,j
Commercial Symyx - MDL, Inc.
Molcode toolbox QSAR-based prediction toola,b,d,i,j Commercial Molcode Ltd.
OECD QSAR toolbox Category formation and read across, QSAR for  
multiple endpoints
Free OECD
Oncologic™ SAR rule-based expert system. Employs  
hierarchical decision tree approachb
Free US EPA
PASS SAR-based expert system using biological activity 
spectra and MNAb,j,o,r
Free geneXplain GmbH
Pre ADMET QSAR-based system and machine learninga,b,l Commercial BMDRC Korea
QikProp QSAR-based expert systemh,l Commercial Schrödinger Inc.
q-TOX Knowledge-based expert systemf,h,j,k,m,n Commercial Quantum pharmaceuticals
Sarah nexus Statistical software toola Commercial Lhasa Ltd.
StarDrop QSAR-based expert systemh Commercial Optibrium Ltd.
T.E.S.T QSAR-based expert system and machine  
learningg,j
Free US EPA
TerraQSAR Molecular fragment QSAR-based expert  
system. Employs probabilistic neural  
networksd,g,j,o
Commercial TerraBase Inc.
TIMES Structural alerts and COREPA software-based  
hybrid expert systema,d,g
Commercial Bourgas University, Bulgaria
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Table 3  continued
Name Particulars Accessibility Owned by
TOPKAT QSAR, SAR, QSTR-based expert system using  
Bayesian classification and partial least square  
regression modelsb,c,d,e,i,j,k,q,
Commercial BIOVIA Discovery Studio®
ToxMatch Category formation and read acrossd Free Ideaconsult Ltd.
ToxTree Category formation and read acrossa,b,c,d,i,l Free Ideaconsult Ltd.
ToxWiz Knowledge base expert system Commercial Cambridge cell networks
AIM analog identification methodology US EPA united states environmental protection agency, FDA food and drugs administration, NTP 
national toxicology program EU European Union, QSAR quantitative structure—activity relationships, QSPR quantitative structure—property 
relationship, QSTR quantitative—structure toxicity relationship, TOPKAT toxicity prediction by computer assisted technology, PASS prediction 
of biological activity spectra for substances, CAESAR computer assisted evaluation of industrial chemical substances according to regulations, 
T.E.S.T toxicity estimation software tool, COMPACT computer-optimized parametric analysis of chemical toxicity, LAZAR lazy structure–activ-
ity relationships, TIMES tissue metabolism simulator, ADMET absorption, distribution, metabolism, excretion, toxicity, MNA multilevel neigh-
bourhood of atoms, COREPA common reactivity pattern approach, ANN artificial neural networks
a Mutagenicity, b carcinogenicity, c genotoxicity, d dermal toxicity, e developmental toxicity, f pulmonary toxicity, g reproductive toxicity, h car-
diotoxicity, I Occular toxicity, j acute toxicity, k hepatotoxicity, l absorption, distribution, metabolism, excretion, m renal toxicity, n neurotoxicity, 
o immunotoxicity, p cytotoxicity, q chronic toxicity, r haemotoxicity, s gastrointestinal toxicity
Fig. 3  a Computational 
toxicology model development 
workflow, b techniques involved 
in different types of predictive 
models
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properties and so on. Algorithms are then required to pre-
process these data as well as for feature extraction. This 
is mainly for selecting the inputs and outputs of models 
as well as to convert raw data into parameters that can be 
modelled mathematically, i.e. profilers or descriptors. Dif-
ferent linear and nonlinear mathematical techniques can be 
used for associating these descriptors to an adverse effect 
or toxicity by means of statistics, rules, multivariate data 
analysis and/or expert knowledge thus leading to develop-
ment of a predictive model as shown in Fig. 3b. The result-
ing model must be validated to ensure non-discriminatory 
comparison with other existing models. Several factors 
would have to be taken into consideration while selecting 
a software platform/tool such as availability, accessibility, 
user expertise levels, transparency of algorithm and knowl-
edge base, choice and complexity of methodology and 
inclusion of mechanistic elucidation. Performance would 
depend on choice of measures for robustness and goodness 
of fit as well as validation parameters and methods chosen. 
Some of these aspects are described in detail in the follow-
ing sections keeping in mind the proteinaceous nature of 
mAbs.
Databases
A number of databases have been utilized for develop-
ing predictive toxicology models during small molecule 
development such as Open TG GATEs, Pharmapendium, 
Drugmatrix® and ToxFX® (Greene and Pennie 2015). 
Databases containing information about mAbs and derived 
therapeutics are being developed extensively, and the IMGT 
mAb database is particularly noteworthy in this regard as 
it provides comprehensive information on structure, pri-
mary sequences, developmental status, targets as well as 
documents relating to approval for more than 589 entities 
(Lefranc et al. 2015). Sources like Drug Bank, patents, 
FDA documents and UniProt could yield useful information 
regarding sequences of mAbs, whereas Protein Data Bank 
(PDB) could provide structural information. The choice 
of a dataset for training model impacts its performance as 
studies have frequently indicated the discrepancies between 
public and proprietary datasets, i.e. performance of a model 
developed on public datasets is lower when applied on a 
proprietary dataset (Greene and Pennie 2015).
Descriptor generation and model development
Multivariate and statistical data analysis techniques have 
further allowed for rapid and easier descriptor calculation 
and model development. For proteins, the primary amino 
acid sequence and in some cases the 3D structure form the 
basis of generating different physicochemical, thermody-
namic and topographic indices where the physicochemical 
and structural characteristics of amino acids are utilized 
to derive descriptors. These include principal component 
analysis-derived descriptors such as z scales and T-scales; 
3D structure-based ones such as isotropic surface area and 
electronic charge index; atomic charge density-derived 
ones such as transferable atomic equivalent, to name a few 
(van Westen et al. 2013a, b). Several machine learning and 
statistical methodologies, such as support vector machines 
(SVM), artificial neural networks (ANNs), k-nearest neigh-
bor approach (kNN), decision forest approach, Naïve 
Bayes, C4.5 decision tree, Bayesian models, random forest 
approaches, recursive partitioning, multiple linear regres-
sion (MLR), discriminant analysis (DA) and self-organiz-
ing maps (SOM), have been used to predict hepatotoxic-
ity, genotoxicity, cardiotoxicity and renal toxicity of small 
molecules (Ekins 2014; Greene and Pennie 2015; Wilson 
2011; Hardy et al. 2010). They can be used to build stan-
dalone inference-based models or combined with quantita-
tive structure–activity relationship modelling.
Models
Quantitative structure–activity relationships (QSAR) 
approach is based on connecting an activity, in particu-
lar toxicity (QSTR) or any other property (QSPR), to 
descriptors which can be derived from physicochemical, 
structural, electronic or steric parameters (Hansch et al. 
1995). QSAR methodology works best when the biologi-
cal activity in question is based on a single endpoint or a 
simplistic mechanism of action. The development of QSAR 
models has been supported extensively by workflow tools, 
QSAR databases as well as uniform reporting and sum-
marizing formats. Expert/Hybrid systems are extension 
of QSAR models, and they can be based on rules, knowl-
edge or statistics as well as a combination of two or more 
approaches. The multivariate techniques used can either 
be linear, such as principal component analysis (PCA) or 
partial least square regression (PLS) used in TOPKAT, or 
nonlinear techniques, such as ANNs, used in CSgenoTox 
(Cronin and Madden 2010). Knowledge-based expert sys-
tems have incorporated a more mechanistic basis to their 
predictive tools (Cronin and Madden 2010). QSAM (quan-
titative sequence activity modelling) is another paradigm 
of QSAR modelling which is being used extensively for 
protein-based predictive models. Angiotensin-converting 
enzyme (ACE)-inhibitory peptides were screened based 
on models generated using PLS, MLR and most recently 
ANN (Zhou et al. 2008). PLS, SVM and HM-based mod-
els have been used with smaller peptides (9 amino acids 
residues) for predicting binding affinity with Class I Major 
Histocompatibility Complex (Zhao et al. 2007). Proteoch-
emometric modelling is an extension of QSAR that uses 
multiplication of ligand and protein descriptors (MLPD) to 
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include interaction space information in addition to protein 
and ligand descriptors (Qiu et al. 2016).
The advantages of QSAR-based expert systems are that 
they are rapid, well developed and regularly updated. The 
disadvantages are that the datasets, algorithms and knowl-
edge base are usually not transparent. Most of the tools 
are commercial and use proprietary datasets. Due to the 
high level of automation, there is a possibility of losing the 
mechanistic understanding of action.
In addition to the models mentioned above, significant 
advances have been made with regard to ADME mod-
els as understanding the ADME characteristics of mol-
ecules is very important in assessing their bioavailability. 
A target mediate drug disposition-based pharmacokinetic 
model has been developed from preclinical data for predict-
ing pharmacokinetics of mAbs within the human system 
which could aid in clinical designs (Luu et al. 2012). There 
have been several machine learning techniques that have 
been employed in skin absorption and metabolizing stud-
ies which enable to predict the extent of toxicity caused by 
compounds (Ashrafi et al. 2015; Moore et al. 2014). It is 
also worthwhile to mention that the latest techniques seem 
to revolve around consensus modelling where the outputs 
from different predictive models are averaged or inferred 
by several approaches, for example, leverage-weighted 
means (Cronin and Madden 2010). The success of these 
models, however, has been debatable as some report bet-
ter predictivity, while others report no significant benefits 
when compared to single models (Hewitt et al. 2007).
Validation
Models are assessed for specificity, sensitivity and concord-
ance based on either a different dataset typically referred to 
as the test set or by other appropriate means of validation. 
Internal validation procedures implemented include cross-
validation (leave out one and/or leave out many) and boot-
strapping. External and independent validation strategies 
can also be used such as testing the model with new experi-
mental data. The predictive ability can be quantified using 
different parameters like root-mean-square error (RMSE), 
determination coefficient (R2) and predictive squared cor-
relation coefficient (Q2) for QSAR model, and these have 
been evaluated in previous studies (Abshear et al. 2006; 
Consonni et al. 2009).
Discussion: status Quo and scope for mAb‑based 
application
Different approaches have to be adopted for safety evalu-
ation of monoclonal antibody-derived therapeutics 
when compared to small molecule drugs owing to innate 
differences like species specificity, degradation, increased 
half-life, complex dose–response relationship, interaction, 
lack of generic testing material, pleiotropic and synergistic 
mechanisms to name a few (Cavagnaro 2002).
Whether it is for assessing preclinical safety or for rapid 
screening, in vivo systems are not the most suitable models 
for studying the effects of monoclonal antibody-based ther-
apeutics. The rationale behind using in vivo studies in pre-
clinical safety testing is that the indirect immune-mediated 
response induced by the antibody as well as the magnitude 
of the effect cannot be gauged via standard in vitro tests. 
However, species specificity still remains the main obsta-
cle. Studying the effector function becomes difficult due 
to differences in the FcγR receptors structure and affinity, 
complement system response and absence of target antigen 
(Golay and Introna 2012). Presence, number, interactions 
as well as distribution of target antigen also play an impor-
tant role in assessing the biological activity of monoclonal 
antibodies (Golay et al. 2001). Attempts have been made to 
solve this problem by different strategies, such as knock-
out mice that lack mouse FcγR, transgenic mice expressing 
human FcγR, generating xenografts with human antigen 
in mouse cell lines, using completely mouse systems and 
using primate models such as rhesus monkey (Golay and 
Introna 2012; Barouch et al. 2013; Bournazos et al. 2014; 
Strasser et al. 2013). Animal testing is also expensive, sam-
ple size dependent and resource intensive. The main bot-
tleneck in using in vitro systems for assessing the toxicity 
of mAbs is that the effector cells have to be coincubated 
or cocultured with the cell line of interest. The sensitivity 
and specificity of these assays depend on several factors 
which have to be optimized, such as cell density, incuba-
tion times as well as the choice of system and assay end-
point. The innate complexity, diversity and size of mAbs-
based therapeutic as well as their diverse mechanisms of 
actions that involve many pathways exacerbate the need for 
carefully designed in vitro systems that take into account 
all of the above factors. In standard cytokine release assays, 
the mAbs bind to receptors all over the cell which is not 
an accurate representation of the human systems where 
cytokine release is sometimes dependent on localized 
receptor interaction (Stebbings et al. 2007). Sophisticated 
analytical techniques used in studying the endpoints of 
these assays have to be carefully assessed for resolution as 
well as sensitivity in detecting events as they can be prone 
to artefacts owing to nature of assay in question as well as 
the size of biological molecules. Artefacts can arise while 
using flow cytometry techniques due to homotypic adhe-
sion as demonstrated with anti CD20 antibodies monoclo-
nal antibodies (Golay et al. 2010). New generation preclini-
cal safety testing tools would have to be high-throughput, 
rapid and cost-effective to meet the accelerated growth of 
the biopharmaceutical market. They also need to be highly 
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reproducible and be fairly predictive to allow for rapid 
screening facilitating reliable selection of new compounds 
at initial stages thus saving time and money to allow more 
focus on drug development for rare diseases. They would 
also provide an alternative to animal testing considering the 
various drawbacks of in vivo systems as seen in the case 
of TGN1412. In vitro systems have now evolved from 2D 
cocultures to 3D spheroidal cocultures, organs on chips as 
well as whole blood systems to better mimic the responses 
that could be produced in a human system (Whritenour 
et al. 2016). Immunotoxicogenomics and expression pro-
filing of both in vivo and in vitro systems are being used 
to identify pathways, mechanism of action as well as bio-
markers for study of delayed hypersensitivity reactions 
(Shao et al. 2014). These advancements may contribute to 
better designed preclinical testing strategies for monoclonal 
antibody-derived therapeutics.
Appropriate and relevant experimental studies are of 
paramount importance in non-clinical safety testing as they 
also contribute to good datasets which can then be mod-
elled. Most of the models are developed based on public 
datasets and fail to perform adequately when tested with 
proprietary datasets. The highly competitive nature of the 
biopharmaceutical industry makes information access very 
difficult. There are also difficulties in feature extraction for 
biological molecules owing to their complexity and size. 
The applicability of such modelling techniques in rapid 
screening depends on the experimental set-up as well as on 
identifying and forming sensible profilers and descriptors. 
Like all proteins, the primary sequence provides a wealth 
of information for mAbs. However, there is high degree of 
sequence similarity, especially in the Fc region, and this 
would mean that appropriate techniques such as bench-
marking would have to be incorporated to select relevant 
descriptor sets (van Westen et al. 2013a, b). Descriptor for 
proteins molecules can be generated by different software 
such as PseAAC, Protein Recon, PROFEAT and ProtDCal, 
of which ProtDCal, a freely available tool with a friendly 
graphical user interface, has the capacity to generate a 
higher number of non-redundant of molecular descriptors 
for proteins from FASTA or PDB files (Ruiz-Blanco et al. 
2015). Another possible concern is that primary sequence-
based descriptors do not take into account neither interac-
tions between amino acid residues nor the antibody-antigen 
and antibody-receptor interaction space. There are dif-
ferent modelling platforms for predicting antibody struc-
tures from primary sequences such as PIGS(Prediction 
of Immunoglobulin Structures), Rosetta antibody, Web 
Antibody Modelling (WAM) and Abysis databases among 
which PIGS performs better (Marcatili et al. 2014). RCSB 
integrates different bioinformatics and structural tools for 
comparison of primary and secondary structures. Advances 
made in PCM techniques include a new descriptor for 
antigen–antibody interaction called epitope–paratope inter-
action fingerprint (EPIF) which tries to address the higher 
time-complexity of MLPD, thus allowing for simplifica-
tion the antigen–antibody interaction term (Qiu et al. 2015, 
2016). Platforms like proABC, ABangle and LYRA allow 
for modelling antigen–antibody interactions, orientation 
of variable chain and lymphocyte receptor, respectively 
(Klausen et al. 2015; Olimpieri et al. 2013; Dunbar et al. 
2013). Physicochemical characteristics of mAbs will influ-
ence PK/PD properties (increased binding to serum pro-
teins and increased half-life) which affects ADME char-
acteristics thus impacting bioavailability and biological 
activity. Glycosylation is another aspect that has to be taken 
into consideration as change in glycosylation pattern could 
affect functionality as well as impact PK/PD characteris-
tics of mAbs (Liu 2015). Successful attempts have been 
made from a bioengineering point of view to investigate the 
effects of the production process on glycosylation profiles 
of monoclonal antibodies by using multivariate techniques, 
such as principal component analysis, partial least squares 
and parallel factor analysis (Green and Glassey 2015; Glas-
sey 2012). Glycoengineered antibodies were produced by 
CHO cells with higher glycosyltransferase which enabled 
the production of engineered antibodies with the N-acetyl-
glucosamine profiles required to achieve higher neutrophil-
mediated phagocytosis activity and thus greater efficacy in 
killing tumour cells (Umaña et al. 1999; Golay et al. 2013). 
Indeed, engineered glycoforms of anti-CD20 antibod-
ies, such as obinutuzumab and rituximab, have sevenfold 
higher binding affinity to neutrophils and thus an increased 
neutrophil-mediated phagocytosis-based killing of tumour 
cells (Golay et al. 2013). The challenge would then be to 
associate these attributes to potential adverse effects which 
will then allow for development of predictive toxicology 
models. Intricate algorithms would also be required for 
associating profilers and descriptors with synergistic end-
points of toxicity. Along with carefully designed experi-
mental procedures, extensive expert knowledge would be 
required for such model development.
Conclusion
Biopharmaceuticals have positively impacted the lives of 
millions. They have paved the way for personalized med-
icines, improve prognosis of cancer, genetic and immune 
disorders as well as breakthroughs in rare disease manage-
ment. The advances made are, however, impeded by a lack 
of progress in bioprocess development strategies as well 
as increasing costs owing to attrition, wherein the lack of 
efficacy and safety accounts for nearly 60 % of all factors 
contributing to attrition (Kola and Landis 2004). This reit-
erates the need for carefully designed predictive models to 
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assess the efficacy as well as toxicity of potential drug can-
didates at an early stage. A more effective, high-throughput 
rapid screening of candidates based on adverse effects is 
required at an early stage to filter out the number of candi-
dates proceeding to clinical trials. A choice of appropriate 
in vivo systems should be in place along with better proof 
of concept studies as animal models are not representative 
of human systems for assessing the efficacy and safety of 
biopharmaceuticals in specialized therapy areas like oncol-
ogy and immunology. Alternative approaches such as spe-
cialized in vitro toxicology tests, better biomarkers and 
omics approaches can be utilized for this purpose. In this 
regard, computational toxicology tools like expert/hybrid 
systems provide a powerful complement to in vitro sys-
tems as they will allow for development of automated and 
reliable models for predicting toxicity or adverse effect of 
monoclonal antibody therapeutics. In order to make these 
predictive platforms more robust, descriptor calculation, 
feature extraction, inclusion of pharmacokinetics and bio-
availability characteristics, mechanistic understanding and 
multidisciplinary expert knowledge will be of paramount 
importance. This will pave way for the development of 
rapid bioprocess development strategies for faster develop-
ment of effective and safe biopharmaceuticals and may in 
fact change the face of biopharmaceutical manufacturing as 
we see today.
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